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Background
With the advent of an aging society, the population of elderly people gradually increases. 
Therefore, menopause-related problems are a prime concern worldwide. In elderly 
women, the incidence of diseases is higher after menopause and if such clinical condi-
tions are ignored, they damage quality of life, interfere with organ function, and may 
even increase the risk of fatal diseases.
Late-onset hypogonadism (LOH), commonly known as andropause, is a clinical and 
biochemical syndrome that is mainly caused by the gradual decrease in testosterone 
levels in men. Patients with LOH typically exhibit aging with a low serum testosterone 
level (Araujo et al. 2004; Jones 2009, 2010). LOH-related symptoms are associated with a 
decrease in total testosterone (TT) levels, cessation of the secretion rhythm, increase in 
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sex hormone-binding globulin (SHBG) levels, and decline in bioavailable free testoster-
one (FT) levels (Wang et al. 2008).
According to a study in the United States, in 2006, up to 600 million US dollars were 
spent on testosterone medication for the treatment of andropause, and other diseases 
related to low testosterone levels in andropause were not included. The results of an aca-
demic survey by the Taiwan Male Medical Association revealed that up to one-third of 
Taiwanese men aged over 40 years had androgen deficiency (based on blood sampling 
tests). Previous studies have revealed that because of the lack of andropause manage-
ment, the life expectancy of men was shorter than that of women (Jones 2009, 2010).
In recent years, an increasing number of scholars have focused on andropause-related 
problems (Wang et  al. 2008; Clapauch et  al. 2008; Cunningham 2006; Gooren 2008; 
Haren et al. 2005; Iwamoto et al. 2009; Kalinchenko et al. 2008; Karazindiyanoğlu and 
Cayan 2008; Kalyani and Dobs 2007; La Vignera et al. 2008; Miner and Seftel 2007; Ros-
ano et  al. 2006; Wu et  al. 2008, 2010). Compared with menopause, the occurrence of 
andropause is more inconsistent, and the symptoms of andropause are also relatively 
mild, which can be easily ignored. This results in a lack of timely and effective clinical 
assessments and hinders the prevention of LOH.
To diagnose LOH, the patient’s blood is sampled to measure the TT or FT levels. If the 
TT level is lower than 300 ng/dl or the FT level is lower than 6.5 ng/dl, then the patient 
has LOH; however, both TT and FT levels are not measured during routine inspections, 
and the tests to determine TT and FT levels are expensive. Few people actively undergo 
this test; therefore, many patients with LOH cannot be identified in a timely manner and 
are not treated. In clinical practice, the Androgen Deficiency in the Aging Male ques-
tionnaire (ADAM) or Aging Males’ Symptoms scale (AMS) are typically used to screen 
men suspected of LOH (Emmelot-Vonk et al. 2011; Heinemann et al. 1992; Heinemann 
2005; Myon et al. 2009; Tancredi et al. 2004; Valenti et al. 2009). Based on the scores, if 
the patient’s assessments match the criteria of andropause symptoms, physicians per-
form blood sampling to confirm the presence of LOH. In other words, ADAM and AMS 
are methods that assist physicians in diagnosing andropause.
The ADAM and AMS are popular, simple, clinical self-assessment methods. In many 
studies, scientists have investigated the correlations between ADAM or AMS and the 
TT level. However, the results have shown no significant correlations between the 
methods and the levels, and the rate of misclassification is high (Wu et al. 2008, 2010; 
Emmelot-Vonk et  al. 2011). Conversely, many studies in recent years have reported 
significant associations between clinical conditions such as the metabolic syndrome, 
obesity, and lower urinary tract symptoms (LUTS), and LOH (Kalinchenko et al. 2008; 
Karazindiyanoğlu and Cayan 2008; Kalyani and Dobs 2007; La Vignera et  al. 2008). 
Moreover, the relevant test data can be easily obtained through routine inspections. If 
LOH can be determined by considering these factors, the accuracy of prediction can be 
increased, which will be helpful in reducing the probability of misclassification of LOH 
and the health care costs in clinical practice.
In this study, we sampled 772 clinical cases in cooperation with the physical examina-
tion center of a medical center in Northern Taiwan. The inclusion criterion for all cases 
in this study was the completion of the ADAM and AMS questionnaires. Two well-
known classification techniques, the decision tree (DT) (Han et al. 2011; Liu et al. 2014; 
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Quinlan 1987) and logistic regression (LGR), were used to construct the LOH prediction 
models on the basis of the aforementioned features. In addition, we also used the Adap-




With the help of National Taiwan University Hospital (NTUH) (the largest medical 
center in Taiwan), data from male patients who completed both the health checkup and 
questionnaires (ADAM and AMS) from October 2008 to November 2009 were obtained 
as the experimental dataset. The NTUH Institutional Review Board approved the study 
protocol (201207058RIC).
After referring to the relevant literature and discussing with physicians, the follow-
ing metabolic syndrome indices were included as the input variables in this study: age, 
4 LUTS indices (Qmax, Qmean, FT, and IPSS), AC sugar, systolic blood pressure (SBP), 
diastolic blood pressure (DBP), triglyceride (TG), high-density lipoprotein (HDL), and 
wrist. Based on patient history, the presence of hypertension was annotated for patients. 
In addition, glycated haemoglobin (HbA1c), body mass index (BMI), total cholesterol, 
PC sugar, obesity, diabetes, and other chronic disease-related information was included. 
Consequently, each data sample contained 16 input variables. Regarding the output vari-
ables, the free testosterone (FT) > 6.5 was defined as having no LOH symptoms and a 
score of FT ≤ 6.5 was defined as having LOH symptoms.
Consequently, raw data from the hospital included 1040 entries. As the baseline for 
this study, we also collected the ADAM and AMS assessment results simultaneously for 
all patients. After confirmation by experts and the deletion of data with missing values 
and outliers, 772 entries were retained for the research datasets to train and test the pre-
diction models. Among these entries were 567 patients with no LOH symptoms and 205 
patients with LOH symptoms. The descriptive statistics are shown in Table 1.
Investigated classification techniques
To construct LOH prediction models, we employed 2 well-known classification proce-
dures, DT and LGR. The DT classifier is a well-known and powerful supervised learning 
technique with a hierarchical structure that comprises nodes and branches (Han et al. 
2011; Liu et  al. 2014; Quinlan 1987). In a DT, an internal node represents one of the 
independent variables, the branch of an internal node represents a subset of the values 
of the corresponding independent variable, and a leaf node is associated with a value 
(or a class label) of the dependent variable. The main advantage of using a DT is that the 
generated rules can be easily observed and interpreted, thus reducing the possibilities of 
mistakes in complex problems.
Many DT-based learning techniques have been developed in the past decades, and 
C4.5, proposed by Quinlan, is the most commonly used technique. The tree-generation 
process for C4.5 consists of the growing and pruning phases. The growing phase adopts 
a divide-and-conquer approach to select suitable variables in an internal node of DT 
and divides the training dataset into subsets by the selected attribute value. This process 
is recursively applied to each internal node (i.e., a subset of the training dataset) until 
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any of the stop criteria are satisfied. At the same time, a class label is assigned to a leaf 
node based on majority voting. The pruning phase reduces the size of a DT to decrease 
the effect of noise on data and avoid over fitting. The prepruning approach is adopted 
by C4.5, which calculates the pessimistic error rate from the training dataset to decide 
when to stop growing a DT.
LGR is a widely used statistical procedure for modeling a dependent variable by a lin-
ear combination of 1 or more independent variables. The main difference between LGR 
and linear regression is that LGR deals with binomial or multinomial classification prob-
lems, whereas linear regression requires the dependent variable to be of interval or ratio 
scales. LGR aims to predict the occurrence probability of an event by fitting data into a 
logistic function, thereby allowing inputs with any values to be transformed and con-
fined to values between 0 and 1.
The classifier ensemble technique was further employed to enhance the prediction 
power of the preceding 2 classification techniques. AdaBoost (Freund and Schapire 
1997) is one of the most well-known classifier ensembles. AdaBoost iteratively applies 
a selected classification algorithm and evaluates each instance in the training dataset. 
For instances incorrectly classified by the current classifier, the misclassification cost 
increases for the next round of learning; in other words, AdaBoost encourages a new 
classifier to learn from instances misclassified by the earlier classifier by assigning a 
larger weight to those instances. After a sequence of classifiers is built, AdaBoost uses a 
weighted majority vote to make predictions. Although the concept of AdaBoost is sim-
ple, previous studies have shown that several classification algorithms in conjunction 
with AdaBoost achieve higher classification accuracy than individual base classifiers do.
Table 1 Summary of input variables of clinical case and descriptive statistics
Input variable Description Range Descriptive statistics
Age Age of aging male (in years) 41–80 μ = 55.61; σ = 7.912
Qmax Maximal flow rate (ml/s) 3–56 μ = 17.62; σ = 7.111
Qmean Average flow rate (ml/s) 2–34 μ = 9.76; σ = 4.173
FT Total flow time (s) 10–119 μ = 35.26; σ = 15.306
IPSS total Total IPSS score 0–33 μ = 8.11; σ = 6.519
SBP Systolic blood pressure (mmHg) 80–169 μ = 123.42; σ = 13.740
DBP Diastolic blood pressure (mmHg) 43–111 μ = 73.77; σ = 9.845
HT Hypertension Yes or no Yes: 315 (40.8 %)
No: 457 (59.2 %)
AC sugar AC Blood Sugar (mg/dl) 69–292 μ = 98.21; σ = 17.885
TG Triglyceride (mg/dl) 31–676 μ = 133.44; σ = 71.750
HDL High‑density lipoprotein (mg/dl) 24–96 μ = 45.65; σ = 9.957
Wrist Wrist (cm) 66.3–114.5 μ = 87.962; σ = 7.5566
HBA1c Glycohemoglobin (%) 4.4–10.4 μ = 5.691; σ = 0.6133
BMI Body mass index (mmHg) 16.7–36.7 μ = 24.807; σ = 2.8593
Total cholesterol Total cholesterol (mg/dL) 95–440 μ = 203.18; σ = 34.138
PC sugar PC blood sugar (mg/dl) 51–408 μ = 127.08; σ = 48.775
LOH Y/N Y: 205 (26.6 %)
N: 567 (73.4 %)
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Experimental setup and performance measurement
The WEKA 3.6.4 open-source data mining software (www.cs.waikato.ac.nz/ml/weka) 
was employed to construct the LOH prediction model. Table 2 lists the specific param-
eter values selected for performing the C4.5, LGR, and AdaBoost classification tech-
niques. In the collection dataset, only 35  % of men were diagnosed with LOH, which 
resulted in class imbalance. Because the adjustment of the ratio of the 2 class samples 
can improve a machine’s learning performance, we used the resampling method in 
WEKA to modify the distribution of instances of the 2 classes to be almost identical. In 
addition, some useful instances in the adequate class were not chosen by the resampling 
method, resulting in the loss of valuable information for classifications. Therefore, the 
random resampling method was applied 30 times to construct datasets. A tenfold cross-
validation method was used in all the experimental evaluations. Because both AMS scale 
and ADAM questionnaire have been widely used in clinical practice for identifying LOH 
patients, we considered the evaluation results of these 2 methods as the baselines.
To evaluate the performance of the constructed classification systems (i.e., prediction 
models), the accuracy, sensitivity, and specificity of each classifier was assessed. These 
were measured using a confusion matrix, as shown in Table 3.
The average prediction accuracy (ACC), sensitivity, and specificity were obtained 
using the following formulas:
(1)Prediction accuracy =
a+ d



















Table 3 Confusion matrix
↓predicted/actual→ LOH symptoms Non-LOH symptoms
LOH symptoms True positive (a) False positive (b)
Non‑LOH symptoms False negative (c) True negative (d)
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Results
The experimental results of each classifier and the baselines are shown in Table 4. Note 
that we generated thirty resampled datasets, resulting in generating thirty results for 
each experiment. All of the experimental evaluations reported in Table 4 are the averages 
of the results of thirty trials. In addition, the cross-validated paired t test was applied 
to compare performances of each pair of classifiers. The ACC values obtained using 
ADAM, AMS, DT, AdaBoost DT, LGR, and AdaBoost LGR, were 0.470, 0.478, 0.825, 
0.851, 0.635, and 0.635, respectively. The results indicated that both ADAM and AMS 
have poor prediction performance in identifying LOH. Among all other classifiers, DT-
based techniques significantly outperformed the LGR techniques at the 0.05 level (DT vs 
LGR: t = 43.268, p < 0.000; DT vs AdaBoost LGR: t = 44.106, p < 0.000; AdaBoost DT vs 
LGR: t = 51.875, p < 0.000; and AdaBoost DT vs AdaBoost LGR: t = 52.824, p < 0.000).
For the other 2 metrics, the sensitivities of ADAM, AMS, DT, AdaBoost DT, LGR, 
and AdaBoost LGR were 0.878, 0.652, 0.840, 0.861, 0.565, and 0.565, respectively. The 
sensitivities of ADAM, AMS, DT, AdaBoost DT, LGR, and AdaBoost LGR were 0.099, 
0.319, 0.812, 0.842, 0.698, and 0.698, respectively. Although the sensitivity of ADAM is 
the highest, it has the lowest specificity, which implies that ADAM overestimates LOH 
occurrence. LGR and AdaBoost LGR tend to have higher specificities and lower sensitiv-
ities. Both DT and AdaBoost DT have relatively stable sensitivity and specificity. In addi-
tion, using the AdaBoost technique can improve the performance in DT, but not in LGR.
Because LOH-affecting factors are highly diverse, diagnosing LOH is difficult. Most 
studies on LOH have focused on identifying the relationships between LOH and other 
diseases. In this study, our aim was to develop a robust LOH prediction model for clini-
cal use. According to the results mentioned in fourth section, neither ADAM nor AMS 
can provide satisfactory predictions for clinical use, and AdaBoost DT was the most 
accurate classifier in our study.
Discussion
In DT classifiers, age was the most crucial variable and thus served as the first attrib-
ute to divide the patients into groups. Other critical variables included PC sugar, wrist, 
TG, HDL, and obesity, which are also used to split the internal nodes of DT. This means 
that the correlations between LOH and obesity or the metabolic syndrome were higher 
than those between LOH and LUTS. In AdaBoost DT classifiers, age remained the most 
critical variable, but metabolic syndrome-related variables (wrist, TG, HDL, hyperten-
sion, and AC sugar) had greater significance than the other variables. Diabetes-related 
Table 4 Experimental results for each classifier
Method ACC Sensitivity Specificity
ADAM 0.470 0.878 0.099
AMS 0.478 0.652 0.319
DT 0.825 0.840 0.812
AdaBoost DT 0.851 0.861 0.842
LGR 0.635 0.565 0.698
AdaBoost LGR 0.635 0.565 0.698
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variables (PC sugar and HBA1c) also appeared in the trees, showing that the metabolic 
syndrome, diabetes, and LOH had significant correlations.
The results of our study are consistent with those of previous studies that have 
explored the relationships between LOH and other diseases. Kalyani and Dobs (2007) 
investigated the relationships among testosterone deficiency syndrome (TDS), comor-
bidity of diabetes, and metabolic syndrome and found that 20–64  % of male patients 
with diabetes exhibited TDS, and it was more prevalent among elderly people. Testoster-
one deficiency may be a risk factor for diabetes and the metabolic syndrome. Conversely, 
the risk factors for diabetes and metabolic syndrome are similar to those for TDS. La 
Vignera et al. (2008) conducted a case study of 60 men (age, 54–63 years) with coexisting 
LOH and metabolic syndrome and found that a good supply of testosterone can alleviate 
the metabolic syndrome. Gooren (2008) found that TT concentration has a significant 
relationship with aging, particularly the metabolic syndrome.
Conclusion
Because of the complexity of the psychological and physiological symptoms of LOH, 
developing an LOH prediction model has thus far been extremely difficult. In this 
study, we used retrospective data to construct an LOH predictive model, using various 
machine learning techniques and compared them with clinical LOH assessment meth-
ods. The results show that AdaBoost DT has the strongest performance and can be used 
in clinical practice. This study provides a stable clinical decision support system that 
helps clinicians in assessing the probability of occurrence of LOH. The system can pro-
vide instantaneous suggestions for a physician’s clinical judgment.
However, our study has limitations. First, the dataset was collected from a single medi-
cal center in Taiwan. The scope of this study can be further expanded to include samples 
from other hospitals. Second, this study only considered LOH-related physical symp-
toms. Other psychological and environmental factors that affect LOH occurrence can 
be considered in model development. Third, other machine learning techniques, such as 
support vector machines and bagging classifier ensembles, can be employed for further 
comparison.
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